Low-grade oligodendroglioma: An indolent but incurable disease? - Clinical article

Journal of Neurosurgery

Volumn 111, Issue 2, 2009, Pages 265-271

  El Hateer, Hamdy ^a   Souhami, Luis ^a,b   Roberge, Davi D ^a   Del Maestro, Rolando ^a   Leblanc, Richard ^a   Eldebawy, Eman ^a   Muanza, Thierry ^a   Melançon, Denis ^a   Kavan, Petr ^a   Guiot, Marie Christine ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Low grade glioma; Oligodendroglioma; Prognostic factor; Survival

Indexed keywords

LOMUSTINE; METHYLTRANSFERASE; O METHYLGUANINE DNA METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME ARM; CHROMOSOME DELETION; CONTRAST ENHANCEMENT; DEMOGRAPHY; FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METHYLATION; OLIGODENDROGLIOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SCORING SYSTEM; SEIZURE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES;

EID: 68849104154     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2008.11.JNS08983     Document Type: Article

References (41)

1. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al: Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45:923-929, 1999 (Pubitemid 29525456)
2. Berger MS, Deliganis AV, Dobbins J, Keles GE: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784-1791, 1994 (Pubitemid 24301834)
3. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006 (Pubitemid 46630566)
4. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152-2165, 1988 (Pubitemid 18261854)
5. Dong SM, Pang JC, Poon WS, Hu J, To KF, Chang AR, et al: Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 60:808-816, 2001 (Pubitemid 32678261)
6. Engelhard HH: Current diagnosis and treatment of oligodendroglioma. Neurosurg Focus 12(2):E2, 2002
7. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, et al: Prognostic value of 1p, 19q, 9p, 10q, and EGFRFISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314-322, 2004 (Pubitemid 38429028)
8. Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, et al: Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol 88:293-298, 2008
9. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861, 2006 (Pubitemid 44672036)
10. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, et al: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52:316-324, 2002 (Pubitemid 34170840)
11. Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95:735-745, 2001
12. Kitange GJ, Templeton KL, Jenkins RB: Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 15:197-203, 2003 (Pubitemid 36735172)
13. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-219, 2002 (Pubitemid 34212595)
14. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y, et al: Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 58:322-326, 2005 (Pubitemid 41098891)
15. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, et al: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14:391-398, 2007 (Pubitemid 46481159)
16. Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, et al: Long-term outcome of oligodendrogliomas. Neurology 62:1783-1787, 2004
17. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, Mac-Donald D, et al: Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294-1301, 1997 (Pubitemid 27167360)
18. Leonardi MA, Lumenta CB: Oligodendrogliomas in the CT/ MR-era. Acta Neurochir (Wien) 143:1195-1203, 2001
19. Maiuri F, Del Basso De Caro ML, Iaconetta G, Peca C, Esposito M, de Divitiis E: Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralbl Neurochir 67:204-209, 2006 (Pubitemid 44951682)
20. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385, 2005 (Pubitemid 40038704)
21. Nijjar TS, Simpson WJ, Gadalla T, McCartney M: Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984). Cancer 71:4002-4006, 1993
22. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al: Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49-56, 2004 (Pubitemid 38961073)
23. Olson JD, Riedel E, DeAngelis LM: Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442-1448, 2000 (Pubitemid 30210463)
24. Ozyigit G, Onal C, Gurkaynak M, Soylemezoglu F, Zorlu F: Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients. J Neurooncol 75:189-193, 2005 (Pubitemid 41819724)
25. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076-2084, 2002 (Pubitemid 34408798)
26. Reiche W, Grunwald I, Hermann K, Deinzer M, Reith W: Oligodendrogliomas. Acta Radiol 43:474-482, 2002
27. Schiff D, Brown PD, Giannini C: Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69:1366-1373, 2007 (Pubitemid 47482451)
28. Shaw E, Arusell R, Scheithauer B, O'Fallon J, O'Neill B, Dinapoli R, et al: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267-2276, 2002 (Pubitemid 34441653)
29. Shaw EG, Berkey B, Coons SW, Brachman D, Buckner JC, Stelzer KJ, et al: Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma. J Clin Oncol 24:18S, 2006 (Abstract)
30. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428-434, 1992
31. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26: 1338-1345, 2008
32. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000 (Pubitemid 30078545)
33. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985-990, 2005 (Pubitemid 41323034)
34. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, et al: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276-1284, 2003 (Pubitemid 36237315)
35. Van den Bent MJ, Reni M, Gatta G, Vecht C: Oligodendroglioma. Crit Rev Oncol Hematol 66:262-272, 2008
36. Vaquero J, Zurita M, Coca S, Oya S, Morales C: Prognostic significance of clinical and angiogenesis-related factors in lowgrade oligodendrogliomas. Surg Neurol 54:229-234, 2000
37. Vaquero J, Zurita M, Morales C, Coca S: Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma. Acta Neurol Scand 106:19-23, 2002 (Pubitemid 34666573)
38. Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, et al: Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 66:1661-1667, 2006 (Pubitemid 43964619)
39. Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, et al: Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933-6937, 2007 (Pubitemid 350276872)
40. White ML, Zhang Y, Kirby P, Ryken TC: Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 26:784-790, 2005 (Pubitemid 43079768)
41. Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, et al: Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 54:1405-1409, 2002 (Pubitemid 35380041)